Published in Nature on April 01, 1986
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol (2008) 7.88
Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity (2007) 5.50
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature (2001) 4.93
Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med (2000) 4.45
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
Evolutionary struggles between NK cells and viruses. Nat Rev Immunol (2008) 3.79
Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood (2011) 3.66
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med (1995) 3.43
NK cell development, homeostasis and function: parallels with CD8⁺ T cells. Nat Rev Immunol (2011) 3.38
The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol (2009) 3.27
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A (2001) 3.21
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med (2009) 3.17
Decreased tumor surveillance in perforin-deficient mice. J Exp Med (1996) 3.00
Isolation and characterization of a protochordate histocompatibility locus. Nature (2005) 2.96
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 2.80
Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science (2010) 2.77
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
The Yin and Yang of HLA and KIR in human disease. Semin Immunol (2008) 2.72
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy (2009) 2.71
MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood (2008) 2.71
Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice. Proc Natl Acad Sci U S A (1991) 2.68
NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med (1994) 2.59
Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A (2005) 2.55
Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A (2003) 2.51
Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res (2010) 2.51
NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol (2013) 2.39
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 2.37
Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci U S A (1989) 2.32
NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J Immunol (2009) 2.12
Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2. Proc Natl Acad Sci U S A (1991) 2.07
Control of adaptive immunity by the innate immune system. Nat Immunol (2015) 2.04
Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell (2011) 2.01
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med (1994) 2.01
Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol (2012) 1.98
DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol (2011) 1.98
Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat Immunol (2010) 1.97
MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med (2010) 1.95
Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med (1994) 1.93
Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type. J Exp Med (1993) 1.93
Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med (2002) 1.88
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med (2012) 1.86
Current perspectives of natural killer cell education by MHC class I molecules. Nat Rev Immunol (2010) 1.83
Latent herpesvirus infection arms NK cells. Blood (2010) 1.80
Macrophages as mediators of tumor immunosurveillance. Trends Immunol (2010) 1.80
A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. Proc Natl Acad Sci U S A (2004) 1.78
Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J Exp Med (2005) 1.76
Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet (2013) 1.75
Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med (1994) 1.74
Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev (2008) 1.74
c-myc down-regulates class I HLA expression in human melanomas. EMBO J (1988) 1.72
Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J Exp Med (2006) 1.72
The speed of change: towards a discontinuity theory of immunity? Nat Rev Immunol (2013) 1.72
Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med (2010) 1.70
Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J Exp Med (2000) 1.69
Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J Exp Med (1987) 1.56
Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood (2008) 1.56
KIR-HLA intercourse in HIV disease. Trends Microbiol (2008) 1.55
Regulation of ligands for the activating receptor NKG2D. Immunology (2007) 1.55
RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J Exp Med (1992) 1.52
Immune evasion of natural killer cells by viruses. Curr Opin Immunol (2008) 1.51
Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med (1998) 1.50
Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med (1990) 1.50
Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov (2015) 1.47
Natural killer cells in infection and inflammation of the lung. Immunology (2009) 1.46
Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood (2005) 1.45
Cytotoxic immunological synapses. Immunol Rev (2010) 1.45
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest (2014) 1.45
Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood (2008) 1.45
Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. J Exp Med (2009) 1.44
Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals. PLoS Pathog (2008) 1.44
Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J Exp Med (1998) 1.43
Adenoviruses of subgenera B, C, D, and E modulate cell-surface expression of major histocompatibility complex class I antigens. Proc Natl Acad Sci U S A (1986) 1.42
Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity? Eur J Immunol (2009) 1.42
CAM and NK Cells. Evid Based Complement Alternat Med (2004) 1.42
Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Proc Natl Acad Sci U S A (1999) 1.40
A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med (1992) 1.39
Activating Receptor Signals Drive Receptor Diversity in Developing Natural Killer Cells. PLoS Biol (2016) 1.38
Peptide influences the folding and intracellular transport of free major histocompatibility complex class I heavy chains. J Exp Med (1995) 1.38
Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene. J Exp Med (1997) 1.38
Skin graft rejection by beta 2-microglobulin-deficient mice. J Exp Med (1992) 1.37
An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med (1998) 1.36
Mechanisms and functions for the duration of intercellular contacts made by lymphocytes. Nat Rev Immunol (2009) 1.36
Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol (2005) 1.35
Zoonotic orthopoxviruses encode a high-affinity antagonist of NKG2D. J Exp Med (2007) 1.34
The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. J Exp Med (2008) 1.34
Natural resistance against lymphoma grafts conveyed by H-2Dd transgene to C57BL mice. J Exp Med (1988) 1.34
Sympathetic modulation of immunity: relevance to disease. Cell Immunol (2008) 1.33
IRG and GBP host resistance factors target aberrant, "non-self" vacuoles characterized by the missing of "self" IRGM proteins. PLoS Pathog (2013) 1.33
Alteration of the natural killer repertoire in H-2 transgenic mice: specificity of rapid lymphoma cell clearance determined by the H-2 phenotype of the target. J Exp Med (1991) 1.33
Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther (2009) 1.32
Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol (1991) 1.31
Self and viral peptides can initiate lysis by autologous natural killer cells. Proc Natl Acad Sci U S A (1997) 1.29
NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses. Blood (2009) 1.29
Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol (2011) 1.28
Altered natural killer cell repertoire in Tap-1 mutant mice. Proc Natl Acad Sci U S A (1994) 1.28
In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today (1990) 10.84
"Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol (1975) 7.61
Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature (1989) 7.11
Empty MHC class I molecules come out in the cold. Nature (1990) 5.53
"Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol (1975) 4.86
Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med (1985) 3.86
Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med (2000) 3.26
An analysis of the murine NK cell as to structure, function and biological relevance. Immunol Rev (1979) 3.15
The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood (2000) 3.09
Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur J Immunol (1977) 3.05
Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice. Proc Natl Acad Sci U S A (1991) 2.68
Role of non-conventional natural killer cells in resistance against syngeneic tumour cells in vivo. Nature (1977) 2.39
Target-effector interaction in the natural killer (NK) cell system. II. The isolation of NK cells and studies on the mechanism of killing. J Immunol (1978) 2.29
Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol (1997) 2.25
Allorecognition by NK cells: nonself or no self? Immunol Today (1992) 2.21
Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems. J Exp Med (1976) 2.11
Prevention of allogeneic bone marrow graft rejection by H-2 transgene in donor mice. Science (1989) 2.08
The recombinant 65-kD heat shock protein of Mycobacterium bovis Bacillus Calmette-Guerin/M. tuberculosis is a target molecule for CD4+ cytotoxic T lymphocytes that lyse human monocytes. J Exp Med (1988) 2.04
Natural killer cells in the mouse: an alternative immune surveillance mechanism? Contemp Top Immunobiol (1978) 1.96
Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res (1993) 1.95
Target--effector interaction in the natural killer cell system. I. Covariance and genetic control of cytolytic and target-cell-binding subpopulations in the mouse. Scand J Immunol (1978) 1.70
Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1) Immunity (1996) 1.69
Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J Exp Med (2000) 1.69
Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med (1994) 1.66
Recognition of autologous dendritic cells by human NK cells. Eur J Immunol (1999) 1.63
Targeting of human dendritic cells by autologous NK cells. J Immunol (1999) 1.62
A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J Exp Med (1997) 1.59
A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol (2001) 1.57
Specific lysis of mycobacterial antigen-bearing macrophages by class II MHC-restricted polyclonal T cell lines in healthy donors or patients with tuberculosis. Clin Exp Immunol (1990) 1.51
Human fetal thymus and bone marrow contain target cells for natural killer cells. Eur J Immunol (1981) 1.51
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol (1996) 1.51
YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol (1985) 1.51
Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med (1998) 1.50
A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer (2004) 1.45
Impaired immune responses and altered peptide repertoire in tapasin-deficient mice. Nat Immunol (2000) 1.44
Low natural in vivo resistance to syngeneic leukaemias in natural killer-deficient mice. Nature (1980) 1.42
CD8+ T cells rapidly acquire NK1.1 and NK cell-associated molecules upon stimulation in vitro and in vivo. J Immunol (2000) 1.41
Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol (2000) 1.40
The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med (1989) 1.39
Natural killer cells. Prog Allergy (1981) 1.38
Peptide influences the folding and intracellular transport of free major histocompatibility complex class I heavy chains. J Exp Med (1995) 1.38
Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene. J Exp Med (1997) 1.38
Natural resistance against lymphoma grafts conveyed by H-2Dd transgene to C57BL mice. J Exp Med (1988) 1.34
Natural killer cells determine development of allergen-induced eosinophilic airway inflammation in mice. J Exp Med (1999) 1.34
Alteration of the natural killer repertoire in H-2 transgenic mice: specificity of rapid lymphoma cell clearance determined by the H-2 phenotype of the target. J Exp Med (1991) 1.33
Altered expression of Ly49 inhibitory receptors on natural killer cells from MHC class I-deficient mice. J Immunol (1997) 1.31
Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci U S A (1992) 1.31
Inhibition of in vitro granulopoiesis by autologous allogeneic human NK cells. J Immunol (1982) 1.30
Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol (2001) 1.30
Natural NK-cell targets in the mouse thymus: characteristics of the sensitive cell population. J Immunol (1979) 1.30
Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer (1995) 1.29
The CD8+ T cell repertoire in beta 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I. J Exp Med (1994) 1.29
Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension (2000) 1.29
Restoration of H-2b expression and processing of endogenous antigens in the MHC class I pathway by fusion of a lymphoma mutant to L cells of the H-2k haplotype. Eur J Immunol (1990) 1.29
T cell responses to fractionated Mycobacterium leprae antigens in leprosy. The lepromatous nonresponder defect can be overcome in vitro by stimulation with fractionated M. leprae components. Eur J Immunol (1989) 1.28
Major histocompatibility complex class I-specific and -restricted killing of beta 2-microglobulin-deficient cells by CD8+ cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1992) 1.28
Presence of human 65 kD heat shock protein (hsp) in inflamed joints and subcutaneous nodules of RA patients. Scand J Immunol (1990) 1.27
In vivo activation of dendritic cells and T cells during Salmonella enterica serovar Typhimurium infection. Infect Immun (2001) 1.26
Peripheral lymphoid development and function in TCR mutant mice. Int Immunol (1994) 1.26
Innate immunity and autoimmunity: from self-protection to self-destruction. Trends Immunol (2001) 1.24
The crystal structure of H-2Dd MHC class I complexed with the HIV-1-derived peptide P18-I10 at 2.4 A resolution: implications for T cell and NK cell recognition. Immunity (1998) 1.23
Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis. J Infect Dis (1990) 1.23
IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-gamma by NK cells. J Immunol (2000) 1.22
Altered phenotype and function of natural killer cells expressing the major histocompatibility complex receptor Ly-49 in mice transgenic for its ligand. Proc Natl Acad Sci U S A (1995) 1.22
NK cell-sensitive T-cell subpopulation in thymus: inverse correlation to host NK activity. Nature (1979) 1.20
The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer (1994) 1.20
Generation of natural killer cells: an autonomous function of the bone marrow. J Exp Med (1977) 1.19
Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants. J Immunol (1990) 1.19
Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts. J Immunol (2000) 1.18
Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line. Int J Cancer (1975) 1.18
Acquisition of external major histocompatibility complex class I molecules by natural killer cells expressing inhibitory Ly49 receptors. J Exp Med (2001) 1.18
Induction of antigen-specific CD4+ HLA-DR-restricted cytotoxic T lymphocytes as well as nonspecific nonrestricted killer cells by the recombinant mycobacterial 65-kDa heat-shock protein. Eur J Immunol (1990) 1.18
Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer (1995) 1.17
A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol (2001) 1.17
T cell competition for the antigen-presenting cell as a model for immunodominance in the cytotoxic T lymphocyte response against minor histocompatibility antigens. Eur J Immunol (1999) 1.17
Immunodominance in the CTL response against minor histocompatibility antigens: interference between responding T cells, rather than with presentation of epitopes. J Immunol (1998) 1.15
Emergence of CD8+ T cells expressing NK cell receptors in influenza A virus-infected mice. J Immunol (2000) 1.15
Target-effector cell interaction in the natural killer cell system. V. Energy requirements, membrane integrity, and the possible involvement of lysosomal enzymes. Immunology (1980) 1.15
Positive selection of self- and alloreactive CD8+ T cells in Tap-1 mutant mice. Proc Natl Acad Sci U S A (1994) 1.15
Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res (2001) 1.12
A functional comparison of tumor cell killing by activated macrophages and natural killer cells. Eur J Immunol (1979) 1.12
Host MHC class I gene control of NK-cell specificity in the mouse. Immunol Rev (1997) 1.10
Restoration of a tumorigenic phenotype by beta 2-microglobulin transfection to EL-4 mutant cells. J Exp Med (1992) 1.10